Thyroid cancer, RET-positive

From HemOnc.org - A Hematology Oncology Wiki
Jump to: navigation, search

Note: these are regimens tested in biomarker-specific populations, please see the main thyroid cancer page for other regimens.

1 regimens on this page
1 variants on this page


Advanced or metastatic disease

Selpercatinib monotherapy

back to top

Regimen

FDA-recommended dose
Study Evidence
Wirth et al. 2020 (LIBRETTO-001) Phase I/II (RT)

Biomarker eligibility criteria

  • RET fusion-positive thyroid cancer
  • RET-mutant medullary thyroid cancer

Chemotherapy

  • Selpercatinib (Retevmo) with or without food, as follows:
    • Less than 50 kg: 120 mg PO twice per day
    • 50 kg or more: 160 mg PO twice per day

Continued indefinitely

References

  1. LIBRETTO-001: Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020 Aug 27;383(9):825-835. link to original article PubMed NCT03157128